The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
复制标题
DOI：
10.1371/journal.pone.0128897
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Brossart P
中科院分区：
文献类型：
--
作者：
Heine A;Held SA;Daecke SN;Riethausen K;Kotthoff P;Flores C;Kurts C;Brossart P
Inhibitors of VEGF receptor (VEGFR) signaling such as sorafenib and sunitinib that are currently used in the treatment of malignant diseases have been shown to affect immunological responses by inhibition of the function of antigen presenting cells and T lymphocytes. The VEGFR-inhibitor axitinib has recently been approved for second line therapy of metastatic renal cell carcinoma. While there is some evidence that axitinib might interfere with the activation of T cells, not much is known about the effects of axitinib on dendritic cell (DC) phenotype and function. We here show that the addition of axitinib during the final Toll-like receptor-4-induced maturation step of monocyte-derived human DCs results in a reduced DC activation characterized by impaired expression of activation markers and co-stimulatory molecules such as CD80, CD83 and CD86. We further found a decreased secretion of interleukin-12 which was accompanied by reduced nuclear expression of the transcription factor cRel. In addition, we found a dose-dependent reduced activation of p38 and STAT3 in axitinib-exposed DCs, whereas the expression was not affected. The dysfunction of axitinib-exposed DCs was further underlined by their impaired induction of allogeneic T cell proliferation in a mixed lymphocyte reaction assay and inhibition of DC migration. Our results demonstrate that axitinib significantly affects DC differentiation and function primarily via the inhibition of the nuclear factor kappa B signaling pathway leading to impaired T cell activation. This will be of importance for the design of future vaccination protocols and therapeutic approaches aiming at combining different treatment strategies, eg such as programmed death-1 inhibitors with axitinib.
登录
查看更多内容
影响因子：
12.4
作者：
Rittig, Susanne M.;Haentschel, Maik;Brossart, Peter
通讯作者：
Brossart, Peter
影响因子：
2.2
作者：
Bose A;Lowe DB;Rao A;Storkus WJ
通讯作者：
Storkus WJ
影响因子：
4.8
作者：
Stehle, Franziska;Schulz, Kristin;Seliger, Barbara
通讯作者：
Seliger, Barbara
影响因子：
20.3
作者：
Heine, Annkristin;Held, Stefanie Andrea Erika;Brossart, Peter
通讯作者：
Brossart, Peter
影响因子：
11.2
作者：
Doloff JC;Waxman DJ
通讯作者：
Waxman DJ